Intellia Therapeutics, Inc. officer and director John M. Leonard filed a Form 144 notice on November 2, 2026, proposing to sell 9,000 shares of Intellia common stock through UBS Financial Services, Inc.

Key Highlights

  • Proposed sale: 9,000 shares of Intellia Therapeutics common stock with an aggregate market value of $113,400.00, according to the filing.
  • Seller: John M. Leonard, listed as both an officer and a director of Intellia Therapeutics, Inc.
  • Shares acquired: The 9,000 shares were acquired on February 9, 2021, via a stock option exercise from the issuer, with cash payment on the same date.
  • Broker: UBS Financial Services, Inc., 11 Madison Ave, 4th Floor, New York, NY 10010, is named as the executing broker.
  • Prior sales: Leonard sold 19,890 shares on August 20, 2026, for gross proceeds of $250,683.26, and 2,789 shares on August 21, 2026, for gross proceeds of $36,205.00 in the three months preceding this filing.
  • Trading plan: The filing indicates reliance on Rule 10b5-1, with a plan adoption date of May 21, 2026.
  • Shares outstanding: The filing reports 140,126,693 shares of common stock outstanding.

Details of the Proposed Sale by Intellia Officer and Director John M. Leonard

According to the Form 144 filed with the U.S. Securities and Exchange Commission on November 2, 2026, John M. Leonard, an officer and director of Intellia Therapeutics, Inc. (NASDAQ:NTLA), proposed to sell 9,000 shares of the company's common stock. The aggregate market value of the proposed sale is listed in the filing as $113,400.00. The approximate date of sale is November 2, 2026, and the sale is to be executed on the NASDAQ exchange through UBS Financial Services, Inc.

The filing discloses that the 9,000 shares subject to this notice were acquired on February 9, 2021, through a stock option exercise from the issuer, with payment made in cash on that same date. The notice was signed by UBS Financial Services Inc. as attorney-in-fact for John Leonard. The filing also notes that the plan of instruction relied upon under Rule 10b5-1 was adopted on May 21, 2026.

The filing further discloses sales by Leonard during the three months prior to this notice: 19,890 shares sold on August 20, 2026, generating gross proceeds of $250,683.26, and an additional 2,789 shares sold on August 21, 2026, generating gross proceeds of $36,205.00. Intellia Therapeutics is headquartered at 400 Technology Square, Suite 100, Cambridge, Massachusetts 02139.

What Was Disclosed

A Form 144 notice was filed on November 2, 2026, by Intellia Therapeutics officer and director John M. Leonard, proposing the sale of 9,000 common shares valued at $113,400.00, with the transaction to be handled by UBS Financial Services, Inc. under a Rule 10b5-1 plan adopted May 21, 2026.